Related Experiment Video
Updated: May 29, 2026
08:07
Personalized Peptide Arrays for Detection of HLA Alloantibodies in Organ Transplantation
Published on: September 6, 2017
Algorithm for donor selection in 2011
William Arcese1, Ilaria Mangione, Alessandra Picardi
1Rome Transplant Network, Department of Haematology, Stem Cell Transplant Unit, Tor Vergata University, Rome, Italy. william.arcese@ptvonline.it
Current Opinion in Hematology
|September 28, 2011
Summary
Timely allogeneic hematopoietic stem cell transplant (ASCT) is crucial for patients with hematological malignancies. Alternative donor sources ensure most patients can receive a transplant, shifting focus from donor availability to transplant necessity.
Area of Science:
- Hematology
- Transplant Immunology
- Oncology
Background:
- Allogeneic hematopoietic stem cell transplant (ASCT) is a critical treatment for hematological malignancies.
- Patient outcome is significantly influenced by the timing of ASCT.
- Identifying suitable donors is essential for successful transplantation.
Purpose of the Study:
- To review recent studies on donor identification for ASCT.
- To outline transplant center policies regarding donor searches.
- To propose an algorithm for timely donor identification to facilitate ASCT.
Main Methods:
- Literature review of recent studies on donor sources and ASCT outcomes.
- Analysis of transplant center policies for donor selection.
- Development of a donor identification algorithm.
Main Results:
- Volunteer-unrelated, umbilical cord blood, and haploidentical-related donors are viable alternatives when HLA-identical siblings are unavailable.
- Current evidence suggests no significant differences in patient outcomes across these alternative donor sources.
- The trend favors a broader search for alternative donors to increase ASCT eligibility.
Conclusions:
- Allogeneic hematopoietic stem cell transplant (ASCT) should be pursued promptly for eligible hematological malignancy patients, irrespective of the stem cell source.
- The treatment paradigm should evolve from 'donor versus no donor' to 'transplant versus no transplant'.
- Optimizing donor identification strategies is key to ensuring timely ASCT and improving patient survival.
